Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | MTOR | P42345 | 1/20 | 0.48 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.48 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.48 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.48 |
| ▸ | SLC29A1 | Q99808 | 10/20 | 0.48 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.47 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.47 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.47 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | THPO | P40225 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30356 | 1.00 | LMNA (0.48) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL14534827 | 0.92 | LMNA (0.49) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL14084325 | 0.92 | LMNA (0.49) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL1062447 | 0.92 | LMNA (0.49) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL29703 | 0.92 | LMNA (0.49) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL29446054 | 0.92 | LMNA (0.49) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL11934657 | 0.83 | SLC29A1 (0.42) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL11934656 | 0.83 | SLC29A1 (0.42) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL650683 | 0.79 | CYP1A2 (0.42) | SLC29A1ADORA3CYP1A2NFKB1THPO | |
| SCHEMBL1777532 | 0.78 | LMNA (0.49) | LMNATHRBMTORMDM2NCOA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 167 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100015708-A1 | RIBONUCLEIC ACIDS WITH NON-STANDARD BASES AND USES THEREOF | MDRNA, INC. (US) | 2010-01-21 | — | — | US | claimed |
| EP-3372684-B1 | SINGLE-STRANDED RNAI AGENTS CONTAINING AN INTERNAL, NON-NUCLEIC ACID SPACER | SIRNA THERAPEUTICS INC (US) | 2020-10-07 | — | — | EP | disclosed |
| US-10584335-B2 | Single-stranded RNAi agents containing an internal, non-nucleic acid spacer | SIRNA THERAPEUTICS, INC. (US) | 2020-03-10 | — | — | US | disclosed |
| US-20200056224-A1 | BARCODED TRANSPOSASES TO INCREASE EFFICIENCY OF HIGH-ACCURACY GENETIC SEQUENCING | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2020-02-20 | — | — | US | disclosed |
| EP-2341943-B1 | COMPOSITIONS AND METHODS FOR THE SPECIFIC INHIBITION OF GENE EXPRESSION BY DSRNA POSSESSING MODIFICATIONS | DICERNA PHARMACEUTICALS INC (US) | 2018-11-07 | — | — | EP | disclosed |
| WO-2018195224-A1 | BARCODED TRANSPOSASES TO INCREASE EFFICIENCY OF HIGH-ACCURACY GENETIC SEQUENCING | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2018-10-25 | — | — | WO | disclosed |
| EP-3372684-A1 | SINGLE-STRANDED RNAI AGENTS CONTAINING AN INTERNAL, NON-NUCLEIC ACID SPACER | Sirna Therapeutics, Inc. (US) | 2018-09-12 | — | — | EP | disclosed |
| US-10023863-B2 | Therapeutics with conformationally restricted monomers | MARINA BIOTECH, INC. (US) | 2018-07-17 | — | — | US | disclosed |
| US-20180119214-A1 | COMPOSITIONS AND METHODS FOR TARGET NUCLEIC ACID MOLECULE ENRICHMENT | FRED HUTCHINSON CANCER RESEARCH CENTER | 2018-05-03 | — | — | US | disclosed |
| US-20180112216-A1 | SEGMENTED MICRO RNA MIMETICS | BANK OF AMERICA, N.A. | 2018-04-26 | — | — | US | disclosed |
| WO-2008109500-A2 | NUCLEIC ACID COMPOUNDS FOR INHIBITING PRKCA GENE EXPRESSION AND USES THEREOF | MDRNA, INC. (US) | 2008-09-12 | — | — | WO | disclosed |
| WO-2008109474-A1 | NUCLEIC ACID COMPOUNDS FOR INHIBITING FGF2 GENE EXPRESSION AND USES THEREOF | MDRNA, INC. (US) | 2008-09-12 | — | — | WO | disclosed |
| WO-2008109470-A2 | NUCLEIC ACID COMPOUNDS FOR INHIBITING PTPN1 GENE EXPRESSION AND USES THEREOF | NASTECH PHARMACEUTICAL COMPANY INC. (US) | 2008-09-12 | — | — | WO | disclosed |
| WO-2008109516-A2 | NUCLEIC ACID COMPOUNDS FOR INHIBITING RAS GENE EXPRESSION AND USES THEREOF | MDRNA, INC. (US) | 2008-09-12 | — | — | WO | disclosed |
| WO-2008109520-A2 | NUCLEIC ACID COMPOUNDS FOR INHIBITING CXC GENE EXPRESSION AND USES THEREOF | MDRNA, INC. (US) | 2008-09-12 | — | — | WO | disclosed |
| WO-2008109558-A2 | NUCLEIC ACID COMPOUNDS FOR INHIBITING TLR GENE EXPRESSION AND USES THEREOF | MDRNA, INC. (US) | 2008-09-12 | — | — | WO | disclosed |
| WO-2008109475-A1 | NUCLEIC ACID COMPOUNDS FOR INHIBITING SIRT2 GENE EXPRESSION AND USES THEREOF | MDRNA, INC. (US) | 2008-09-12 | — | — | WO | disclosed |
| WO-2008109492-A1 | NUCLEIC ACID COMPOUNDS FOR INHIBITING IGF1R GENE EXPRESSION AND USES THEREOF | MDRNA, INC. (US) | 2008-09-12 | — | — | WO | disclosed |
| WO-2008109366-A2 | NUCLEIC ACID COMPOUNDS FOR INHIBITING CCND1 GENE EXPRESSION AND USES THEREOF | MDRNA, INC. (US) | 2008-09-12 | — | — | WO | disclosed |
| US-20080076701-A1 | DICER SUBSTRATE RNA PEPTIDE CONJUGATES AND METHODS FOR RNA THERAPEUTICS | NASTECH PHARMACEUTICAL COMPANY INC. (US) | 2008-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076701-A1 | DICER SUBSTRATE RNA PEPTIDE CONJUGATES AND METHODS FOR RNA THERAPEUTICS | RNASE1, SARNP, AGO2 | LMNA 1631/4885THRB 2819/4885MTOR 4123/4885 |
| US-20100015708-A1 | RIBONUCLEIC ACIDS WITH NON-STANDARD BASES AND USES THEREOF | NSUN2, NSUN3, RNMT | LMNA 1906/4885THRB 3912/4885MTOR 4225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.